Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro is a once-weekly subcutaneous injection containing tirzepatide, licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 and above alongside a weight-related health condition. Each pre-filled KwikPen delivers four weekly doses, starting at 2.5 mg to help your body adjust gradually. Like all prescription-only medicines, it requires a clinical assessment before a prescriber can issue it. The information below is designed to help you arrive at that conversation well-prepared, understanding how the injection works, what to expect week to week, and which questions are worth raising with your clinician.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro is injected under the skin, not into a muscle. The three licensed sites are the abdomen (at least a few centimetres from the navel), the front of the thigh, and the outer upper arm. Each works equally well in clinical terms, so the choice comes down to what is practical and comfortable for you.
Rotation is not just a recommendation — it is the reason the three sites exist. Injecting into the same small area repeatedly can cause the fatty tissue beneath the skin to thicken or harden, a process called lipohypertrophy, which slows absorption and reduces how reliably the medicine works. A good habit is to move around the same site (for example, different parts of the abdomen across a month) and to alternate sites from week to week. Our guide to Mounjaro injection sites covers this in more detail, including how to check the skin before injecting.
The upper arm is the trickiest site to self-inject if you are alone, and if you want to understand the technique in detail, our page on Mounjaro arm injection explains how to hold the pen steady and what to watch for when injecting into that area. A question our prescribers hear most weeks is whether the arm is as effective as the abdomen, it is, provided the technique is consistent. If you find one site repeatedly uncomfortable, mention it at your next clinical check-in rather than switching doses or timing.
The 2.5 mg starting dose exists for one reason: to let your digestive system adapt. At this strength, the effect on appetite is modest; the job of the first pen is to reduce the chance of nausea and vomiting making the first weeks miserable, not to drive significant weight loss. That is a normal and expected part of the process, not a sign that the medicine is not working.
Increases happen in four-week steps (from 2.5 mg to 5 mg, then 7.5, 10, 12.5, and up to 15 mg if tolerated) and each step is a clinical decision, not an automatic progression. If side effects at a given dose are still significant, a prescriber may hold you at the same strength for another four weeks rather than push upward. Chasing the highest dose as quickly as possible is not the aim; finding the dose that balances tolerability with effect is.
For a full walkthrough of what each step involves physically, the step-by-step Mounjaro injection guide on our site covers pen preparation, priming, site selection, and what to do if you have a question about a missed dose. The NHS medicines page for tirzepatide also contains clear, plain-English information on the titration schedule and what to discuss with your prescriber.
Gastrointestinal effects are the most commonly reported: nausea, loose stools, constipation, burping, indigestion, and a feeling of fullness that can arrive quickly during meals. These are direct consequences of the medicine slowing gastric emptying, and for most people they are front-loaded, worse in the first week or two after a dose change and then settling. Staying well-hydrated and eating smaller, lower-fat meals during that window can help.
Less common but worth knowing: headache, dizziness, fatigue, and injection-site redness or itching. These typically resolve without intervention.
A small number of people develop more serious reactions. Seek urgent medical attention for severe, persistent stomach pain that spreads toward the back, with or without vomiting, this could indicate acute pancreatitis, which the MHRA highlighted in a Drug Safety Update in January 2026 as an infrequent but serious risk with GLP-1 medicines. Symptoms of a severe allergic reaction, gallbladder pain, or signs of significant dehydration after repeated vomiting also warrant same-day medical contact rather than waiting for a scheduled review. You can report any suspected side effect through the MHRA Yellow Card scheme.
Mounjaro is a prescription-only medicine. That means it cannot legally be supplied without a prescription issued following a genuine clinical assessment, regardless of where you obtain it. The counterfeit market for GLP-1 pens is active and dangerous, and our page on Mounjaro injection pens explains what to look for to verify that a pen is genuine before you use it. Fake pens have been found to contain insulin rather than tirzepatide, with serious consequences for some people who bought from unverified online sources.
The safest way to verify any online pharmacy is to check the GPhC register before placing an order. A registered pharmacy is legally accountable; an unregistered one is not. At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, and medicines are dispensed through our own GPhC-registered pharmacy. Details about the clinical team behind the service are on our prescriber profile page.
If you are thinking about what private treatment actually costs and what a legitimate price includes, the Mounjaro cost page sets out the picture honestly. The short version: a legitimate price always includes the clinical assessment and prescription, not just the pen.
If you would like to explore whether Mounjaro is suitable for you, our page on the Mounjaro injection gives a clear overview of how treatment works before you take the next step. You can also start a free consultation with our prescribers at any point. There is no obligation, and the assessment is thorough.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.